Attenuation of TORC1 signaling delays replicative and oncogenic RAS-induced senescence

References

• Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479:547 - 51; http://dx.doi.org/10.1038/nature10599; PMID: 22080947
   PubMed Web of Science ®Google Scholar
• Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol 2011; 192:547 - 56; http://dx.doi.org/10.1083/jcb.201009094; PMID: 21321098
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV. Cell cycle arrest is not senescence. Aging 2011; 3:94 - 101; PMID: 21297220
   PubMedGoogle Scholar
• Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007; 130:223 - 33; http://dx.doi.org/10.1016/j.cell.2007.07.003; PMID: 17662938
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev 2010; 24:2463 - 79; http://dx.doi.org/10.1101/gad.1971610; PMID: 21078816
   PubMed Web of Science ®Google Scholar
• Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88:593 - 602; http://dx.doi.org/10.1016/S0092-8674(00)81902-9; PMID: 9054499
   PubMed Web of Science ®Google Scholar
• DeNicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur J Cancer 2009; 45:Suppl 1 211 - 6; http://dx.doi.org/10.1016/S0959-8049(09)70036-X; PMID: 19775620
   PubMedGoogle Scholar
• Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002; 31:210 - 5; http://dx.doi.org/10.1038/ng894; PMID: 12021785
   PubMed Web of Science ®Google Scholar
• Wang W, Chen JX, Liao R, Deng Q, Zhou JJ, Huang S, et al. Sequential activation of the MEK-extracellular signal-regulated kinase and MKK3/6-p38 mitogen-activated protein kinase pathways mediates oncogenic ras-induced premature senescence. Mol Cell Biol 2002; 22:3389 - 403; http://dx.doi.org/10.1128/MCB.22.10.3389-3403.2002; PMID: 11971971
   PubMed Web of Science ®Google Scholar
• Bulavin DV, Kovalsky O, Hollander MC, Fornace AJ Jr.. Loss of oncogenic H-ras-induced cell cycle arrest and p38 mitogen-activated protein kinase activation by disruption of Gadd45a. Mol Cell Biol 2003; 23:3859 - 71; http://dx.doi.org/10.1128/MCB.23.11.3859-3871.2003; PMID: 12748288
   PubMed Web of Science ®Google Scholar
• Han J, Sun P. The pathways to tumor suppression via route p38. Trends Biochem Sci 2007; 32:364 - 71; http://dx.doi.org/10.1016/j.tibs.2007.06.007; PMID: 17624785
   PubMed Web of Science ®Google Scholar
• Sun P, Yoshizuka N, New L, Moser BA, Li Y, Liao R, et al. PRAK is essential for ras-induced senescence and tumor suppression. Cell 2007; 128:295 - 308; http://dx.doi.org/10.1016/j.cell.2006.11.050; PMID: 17254968
   PubMed Web of Science ®Google Scholar
• Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638 - 42; http://dx.doi.org/10.1038/nature05327; PMID: 17136094
   PubMed Web of Science ®Google Scholar
• Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21:43 - 8; http://dx.doi.org/10.1101/gad.1487307; PMID: 17210786
   PubMed Web of Science ®Google Scholar
• Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25:585 - 621; http://dx.doi.org/10.1016/0014-4827(61)90192-6
   PubMed Web of Science ®Google Scholar
• Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43:405 - 13; http://dx.doi.org/10.1016/0092-8674(85)90170-9; PMID: 3907856
   PubMed Web of Science ®Google Scholar
• d’Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426:194 - 8; http://dx.doi.org/10.1038/nature02118; PMID: 14608368
   PubMed Web of Science ®Google Scholar
• Gire V, Roux P, Wynford-Thomas D, Brondello JM, Dulic V. DNA damage checkpoint kinase Chk2 triggers replicative senescence. EMBO J 2004; 23:2554 - 63; http://dx.doi.org/10.1038/sj.emboj.7600259; PMID: 15192702
   PubMed Web of Science ®Google Scholar
• Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196:33 - 9; http://dx.doi.org/10.1016/0014-4827(91)90453-2; PMID: 1652450
   PubMed Web of Science ®Google Scholar
• Deng Q, Liao R, Wu BL, Sun P. High intensity ras signaling induces premature senescence by activating p38 pathway in primary human fibroblasts. J Biol Chem 2004; 279:1050 - 9; http://dx.doi.org/10.1074/jbc.M308644200; PMID: 14593117
   PubMed Web of Science ®Google Scholar
• Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92:9363 - 7; http://dx.doi.org/10.1073/pnas.92.20.9363; PMID: 7568133
   PubMed Web of Science ®Google Scholar
• Freund A, Patil CK, Campisi J. p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J 2011; 30:1536 - 48; http://dx.doi.org/10.1038/emboj.2011.69; PMID: 21399611
   PubMed Web of Science ®Google Scholar
• Iwasa H, Han J, Ishikawa F. Mitogen-activated protein kinase p38 defines the common senescence-signalling pathway. Genes Cells 2003; 8:131 - 44; http://dx.doi.org/10.1046/j.1365-2443.2003.00620.x; PMID: 12581156
   PubMed Web of Science ®Google Scholar
• Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211:90 - 8; http://dx.doi.org/10.1006/excr.1994.1063; PMID: 8125163
   PubMed Web of Science ®Google Scholar
• Beauséjour CM, Krtolica A, Galimi F, Narita M, Lowe SW, Yaswen P, et al. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J 2003; 22:4212 - 22; http://dx.doi.org/10.1093/emboj/cdg417; PMID: 12912919
   PubMed Web of Science ®Google Scholar
• Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, et al. Extension of life-span by introduction of telomerase into normal human cells. Science 1998; 279:349 - 52; http://dx.doi.org/10.1126/science.279.5349.349; PMID: 9454332
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Zubova SG, Bukreeva EI, Pospelov VA, Pospelova TV, Blagosklonny MV. Rapamycin decelerates cellular senescence. Cell Cycle 2009; 8:1888 - 95; http://dx.doi.org/10.4161/cc.8.12.8606; PMID: 19471117
   PubMed Web of Science ®Google Scholar
• Leontieva OV, Blagosklonny MV. DNA damaging agents and p53 do not cause senescence in quiescent cells, while consecutive re-activation of mTOR is associated with conversion to senescence. Aging 2010; 2:924 - 35; PMID: 21212465
   PubMedGoogle Scholar
• Blagosklonny MV. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Aging 2012; 4:159 - 65; PMID: 22394614
   PubMedGoogle Scholar
• Jiang H, Vogt PK. Constitutively active Rheb induces oncogenic transformation. Oncogene 2008; 27:5729 - 40; http://dx.doi.org/10.1038/onc.2008.180; PMID: 18521078
   PubMed Web of Science ®Google Scholar
• Chang HW, Aoki M, Fruman D, Auger KR, Bellacosa A, Tsichlis PN, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997; 276:1848 - 50; http://dx.doi.org/10.1126/science.276.5320.1848; PMID: 9188528
   PubMed Web of Science ®Google Scholar
• Staal SP. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. Proc Natl Acad Sci USA 1987; 84:5034 - 7; http://dx.doi.org/10.1073/pnas.84.14.5034; PMID: 3037531
   PubMed Web of Science ®Google Scholar
• Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010; 347:79 - 104; http://dx.doi.org/10.1007/82_2010_80; PMID: 20582532
   PubMed Web of Science ®Google Scholar
• Aoki M, Batista O, Bellacosa A, Tsichlis P, Vogt PK. The akt kinase: molecular determinants of oncogenicity. Proc Natl Acad Sci USA 1998; 95:14950 - 5; http://dx.doi.org/10.1073/pnas.95.25.14950; PMID: 9843996
   PubMed Web of Science ®Google Scholar
• Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27:5486 - 96; http://dx.doi.org/10.1038/onc.2008.244; PMID: 18794883
   PubMed Web of Science ®Google Scholar
• Ciraolo E, Morello F, Hirsch E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr Med Chem 2011; 18:2674 - 85; http://dx.doi.org/10.2174/092986711796011193; PMID: 21649577
   PubMed Web of Science ®Google Scholar
• Dancey J. mTOR signaling and drug development in cancer. Nature reviews. Clin Oncol 2010; 7:209 - 19
   Web of Science ®Google Scholar
• Vanhaesebroeck B, Vogt PK, Rommel C. PI3K: from the bench to the clinic and back. Curr Top Microbiol Immunol 2010; 347:1 - 19; http://dx.doi.org/10.1007/82_2010_65; PMID: 20549473
   PubMed Web of Science ®Google Scholar
• O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500 - 8; http://dx.doi.org/10.1158/0008-5472.CAN-05-2925; PMID: 16452206
   PubMed Web of Science ®Google Scholar
• Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008; 27:1932 - 43; http://dx.doi.org/10.1038/emboj.2008.120; PMID: 18566586
   PubMed Web of Science ®Google Scholar
• Dibble CC, Asara JM, Manning BD. Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1. Mol Cell Biol 2009; 29:5657 - 70; http://dx.doi.org/10.1128/MCB.00735-09; PMID: 19720745
   PubMed Web of Science ®Google Scholar
• Efeyan A, Sabatini DM. mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 2010; 22:169 - 76; http://dx.doi.org/10.1016/j.ceb.2009.10.007; PMID: 19945836
   PubMed Web of Science ®Google Scholar
• Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008; 118:3065 - 74; PMID: 18725988
   PubMed Web of Science ®Google Scholar
• Lempiäinen H, Halazonetis TD. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J 2009; 28:3067 - 73; http://dx.doi.org/10.1038/emboj.2009.281; PMID: 19779456
   PubMed Web of Science ®Google Scholar
• Loewith R, Jacinto E, Wullschleger S, Lorberg A, Crespo JL, Bonenfant D, et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002; 10:457 - 68; http://dx.doi.org/10.1016/S1097-2765(02)00636-6; PMID: 12408816
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004; 14:1296 - 302; http://dx.doi.org/10.1016/j.cub.2004.06.054; PMID: 15268862
   PubMed Web of Science ®Google Scholar
• Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122 - 8; http://dx.doi.org/10.1038/ncb1183; PMID: 15467718
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18:1926 - 45; http://dx.doi.org/10.1101/gad.1212704; PMID: 15314020
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21 - 35; http://dx.doi.org/10.1038/nrm3025; PMID: 21157483
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098 - 101; http://dx.doi.org/10.1126/science.1106148; PMID: 15718470
   PubMed Web of Science ®Google Scholar
• Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127:125 - 37; http://dx.doi.org/10.1016/j.cell.2006.08.033; PMID: 16962653
   PubMed Web of Science ®Google Scholar
• Burnett PE, Barrow RK, Cohen NA, Snyder SH, Sabatini DM. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 1998; 95:1432 - 7; http://dx.doi.org/10.1073/pnas.95.4.1432; PMID: 9465032
   PubMed Web of Science ®Google Scholar
• Gingras AC, Kennedy SG, O’Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998; 12:502 - 13; http://dx.doi.org/10.1101/gad.12.4.502; PMID: 9472019
   PubMed Web of Science ®Google Scholar
• Ruvinsky I, Sharon N, Lerer T, Cohen H, Stolovich-Rain M, Nir T, et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 2005; 19:2199 - 211; http://dx.doi.org/10.1101/gad.351605; PMID: 16166381
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, et al. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 2001; 15:2852 - 64; PMID: 11691836
   PubMed Web of Science ®Google Scholar
• Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J 1995; 14:5701 - 9; PMID: 8521827
   PubMed Web of Science ®Google Scholar
• Petroulakis E, Parsyan A, Dowling RJ, LeBacquer O, Martineau Y, Bidinosti M, et al. p53-dependent translational control of senescence and transformation via 4E-BPs. Cancer Cell 2009; 16:439 - 46; http://dx.doi.org/10.1016/j.ccr.2009.09.025; PMID: 19878875
   PubMed Web of Science ®Google Scholar
• Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133:1019 - 31; http://dx.doi.org/10.1016/j.cell.2008.03.039; PMID: 18555778
   PubMed Web of Science ®Google Scholar
• Orjalo AV, Bhaumik D, Gengler BK, Scott GK, Campisi J. Cell surface-bound IL-1alpha is an upstream regulator of the senescence-associated IL-6/IL-8 cytokine network. Proc Natl Acad Sci USA 2009; 106:17031 - 6; http://dx.doi.org/10.1073/pnas.0905299106; PMID: 19805069
   PubMed Web of Science ®Google Scholar
• Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci USA 1995; 92:8348 - 52; http://dx.doi.org/10.1073/pnas.92.18.8348; PMID: 7667293
   PubMed Web of Science ®Google Scholar
• Webley K, Bond JA, Jones CJ, Blaydes JP, Craig A, Hupp T, et al. Posttranslational modifications of p53 in replicative senescence overlapping but distinct from those induced by DNA damage. Mol Cell Biol 2000; 20:2803 - 8; http://dx.doi.org/10.1128/MCB.20.8.2803-2808.2000; PMID: 10733583
   PubMed Web of Science ®Google Scholar
• Rousseau D, Kaspar R, Rosenwald I, Gehrke L, Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proc Natl Acad Sci USA 1996; 93:1065 - 70; http://dx.doi.org/10.1073/pnas.93.3.1065; PMID: 8577715
   PubMed Web of Science ®Google Scholar
• Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem 2012; 287:9742 - 52; http://dx.doi.org/10.1074/jbc.M111.304485; PMID: 22223645
   PubMed Web of Science ®Google Scholar
• Hara K, Maruki Y, Long X, Yoshino K, Oshiro N, Hidayat S, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002; 110:177 - 89; http://dx.doi.org/10.1016/S0092-8674(02)00833-4; PMID: 12150926
   PubMed Web of Science ®Google Scholar
• Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002; 110:163 - 75; http://dx.doi.org/10.1016/S0092-8674(02)00808-5; PMID: 12150925
   PubMed Web of Science ®Google Scholar
• Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006; 124:471 - 84; http://dx.doi.org/10.1016/j.cell.2006.01.016; PMID: 16469695
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22:159 - 68; http://dx.doi.org/10.1016/j.molcel.2006.03.029; PMID: 16603397
   PubMed Web of Science ®Google Scholar
• Brugarolas J, Lei K, Hurley RL, Manning BD, Reiling JH, Hafen E, et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 2004; 18:2893 - 904; http://dx.doi.org/10.1101/gad.1256804; PMID: 15545625
   PubMed Web of Science ®Google Scholar
• Wang H, Kubica N, Ellisen LW, Jefferson LS, Kimball SR. Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem 2006; 281:39128 - 34; http://dx.doi.org/10.1074/jbc.M610023200; PMID: 17074751
   PubMed Web of Science ®Google Scholar
• Molitoris JK, McColl KS, Swerdlow S, Matsuyama M, Lam M, Finkel TH, et al. Glucocorticoid elevation of dexamethasone-induced gene 2 (Dig2/RTP801/REDD1) protein mediates autophagy in lymphocytes. J Biol Chem 2011; 286:30181 - 9; http://dx.doi.org/10.1074/jbc.M111.245423; PMID: 21733849
   PubMed Web of Science ®Google Scholar
• Corradetti MN, Inoki K, Guan KL. The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway. J Biol Chem 2005; 280:9769 - 72; http://dx.doi.org/10.1074/jbc.C400557200; PMID: 15632201
   PubMed Web of Science ®Google Scholar
• Ruggero D, Montanaro L, Ma L, Xu W, Londei P, Cordon-Cardo C, et al. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 2004; 10:484 - 6; http://dx.doi.org/10.1038/nm1042; PMID: 15098029
   PubMed Web of Science ®Google Scholar
• Dulić V, Drullinger LF, Lees E, Reed SI, Stein GH. Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci USA 1993; 90:11034 - 8; http://dx.doi.org/10.1073/pnas.90.23.11034; PMID: 8248208
   PubMed Web of Science ®Google Scholar
• Fang L, Igarashi M, Leung J, Sugrue MM, Lee SW, Aaronson SA. p21Waf1/Cip1/Sdi1 induces permanent growth arrest with markers of replicative senescence in human tumor cells lacking functional p53. Oncogene 1999; 18:2789 - 97; http://dx.doi.org/10.1038/sj.onc.1202615; PMID: 10362249
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Korotchkina LG, Gudkov AV, Blagosklonny MV. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci USA 2010; 107:9660 - 4; http://dx.doi.org/10.1073/pnas.1002298107; PMID: 20457898
   PubMed Web of Science ®Google Scholar
• Demidenko ZN, Shtutman M, Blagosklonny MV. Pharmacologic inhibition of MEK and PI-3K converges on the mTOR/S6 pathway to decelerate cellular senescence. Cell Cycle 2009; 8:1896 - 900; http://dx.doi.org/10.4161/cc.8.12.8809; PMID: 19478560
   PubMed Web of Science ®Google Scholar
• Harrington LS, Findlay GM, Lamb RF. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem Sci 2005; 30:35 - 42; http://dx.doi.org/10.1016/j.tibs.2004.11.003; PMID: 15653324
   PubMed Web of Science ®Google Scholar
• Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995; 270:1326 - 31; http://dx.doi.org/10.1126/science.270.5240.1326; PMID: 7481820
   PubMed Web of Science ®Google Scholar
• Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998; 282:1318 - 21; http://dx.doi.org/10.1126/science.282.5392.1318; PMID: 9812896
   PubMed Web of Science ®Google Scholar
• Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997; 91:231 - 41; http://dx.doi.org/10.1016/S0092-8674(00)80405-5; PMID: 9346240
   PubMed Web of Science ®Google Scholar
• del Peso L, González-García M, Page C, Herrera R, Nuñez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278:687 - 9; http://dx.doi.org/10.1126/science.278.5338.687; PMID: 9381178
   PubMed Web of Science ®Google Scholar
• Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002; 8:1153 - 60; http://dx.doi.org/10.1038/nm761; PMID: 12244302
   PubMed Web of Science ®Google Scholar
• Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 2001; 98:11598 - 603; http://dx.doi.org/10.1073/pnas.181181198; PMID: 11504915
   PubMed Web of Science ®Google Scholar
• Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002; 8:1145 - 52; http://dx.doi.org/10.1038/nm759; PMID: 12244301
   PubMed Web of Science ®Google Scholar
• Tran H, Brunet A, Griffith EC, Greenberg ME. The many forks in FOXO’s road. Sci STKE 2003; 2003:RE5; http://dx.doi.org/10.1126/stke.2003.172.re5; PMID: 12621150
   PubMedGoogle Scholar
• Viglietto G, Motti ML, Bruni P, Melillo RM, D’Alessio A, Califano D, et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002; 8:1136 - 44; http://dx.doi.org/10.1038/nm762; PMID: 12244303
   PubMed Web of Science ®Google Scholar
• Feng J, Park J, Cron P, Hess D, Hemmings BA. Identification of a PKB/Akt hydrophobic motif Ser-473 kinase as DNA-dependent protein kinase. J Biol Chem 2004; 279:41189 - 96; http://dx.doi.org/10.1074/jbc.M406731200; PMID: 15262962
   PubMed Web of Science ®Google Scholar
• Viniegra JG, Martínez N, Modirassari P, Hernández Losa J, Parada Cobo C, Sánchez-Arévalo Lobo VJ, et al. Full activation of PKB/Akt in response to insulin or ionizing radiation is mediated through ATM. J Biol Chem 2005; 280:4029 - 36; http://dx.doi.org/10.1074/jbc.M410344200; PMID: 15546863
   PubMed Web of Science ®Google Scholar
• Hresko RC, Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem 2005; 280:40406 - 16; http://dx.doi.org/10.1074/jbc.M508361200; PMID: 16221682
   PubMed Web of Science ®Google Scholar
• Yellen P, Saqcena M, Salloum D, Feng J, Preda A, Xu L, et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011; 10:3948 - 56; http://dx.doi.org/10.4161/cc.10.22.18124; PMID: 22071574
   PubMed Web of Science ®Google Scholar
• Xie X, Zhang D, Zhao B, Lu MK, You M, Condorelli G, et al. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc Natl Acad Sci USA 2011; 108:6474 - 9; http://dx.doi.org/10.1073/pnas.1016132108; PMID: 21464307
   PubMed Web of Science ®Google Scholar
• Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011; 41:458 - 70; http://dx.doi.org/10.1016/j.molcel.2011.01.019; PMID: 21329883
   PubMed Web of Science ®Google Scholar
• Kennedy AL, Morton JP, Manoharan I, Nelson DM, Jamieson NB, Pawlikowski JS, et al. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 2011; 42:36 - 49; http://dx.doi.org/10.1016/j.molcel.2011.02.020; PMID: 21474066
   PubMed Web of Science ®Google Scholar
• Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, et al. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 2011; PMID: 21909130
   PubMed Web of Science ®Google Scholar
• Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005; 433:477 - 80; http://dx.doi.org/10.1038/nature03205; PMID: 15690031
   PubMed Web of Science ®Google Scholar
• Kang HT, Lee KB, Kim SY, Choi HR, Park SC. Autophagy impairment induces premature senescence in primary human fibroblasts. PLoS ONE 2011; 6:e23367; http://dx.doi.org/10.1371/journal.pone.0023367; PMID: 21858089
   PubMed Web of Science ®Google Scholar
• Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov 2011; 10:868 - 80; http://dx.doi.org/10.1038/nrd3531; PMID: 22037041
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129:1261 - 74; http://dx.doi.org/10.1016/j.cell.2007.06.009; PMID: 17604717
   PubMed Web of Science ®Google Scholar